Manchester Capital Management’s Solid Biosciences SLDB Stock Holding History

Manchester Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000	Closed	-$2.52K	–	1075
2023 Q3	$2.52K	Hold	1,000	–	–	﹤0.01%	740
2023 Q2	$5.24K	Hold	1,000	–	–	﹤0.01%	613
2023 Q1	$4.74K	Hold	1,000	–	–	﹤0.01%	627
2022 Q4	$5.38K	Buy	+1,000	New	+$6.55K	﹤0.01%	520
2022 Q2	–	Sell	-667	Closed	-$12K	–	1124
2022 Q1	$12K	Hold	667	–	–	﹤0.01%	523
2021 Q4	$18K	Hold	667	–	–	﹤0.01%	493
2021 Q3	$24K	Buy	+667	New	+$28.3K	﹤0.01%	492

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manchester Capital Management's SLDB Position: Q4 2023 in Review

Manchester Capital Management sold out of Solid Biosciences (SLDB) in Q4 2023, closing a stake of 1,000 shares — an estimated $2.52K sold.

Manchester Capital Management first reported a position in SLDB in Q3 2021 and held it in 7 quarters. The position peaked at $24K in Q3 2021. 39 funds tracked by Wall St. Rank hold SLDB as of Q4 2023.

Manchester Capital Management reported no remaining Solid Biosciences position as of Q4 2023 after selling out during the quarter.
Manchester Capital Management sold 1,000 Solid Biosciences shares in Q4 2023, an estimated $2.52K.
Manchester Capital Management first reported a position in Solid Biosciences in Q3 2021 and held it in 7 quarters.
Manchester Capital Management's Solid Biosciences position peaked at $24K in Q3 2021.
39 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2023.

Based on Manchester Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.